Walmsley, Charlotte S.
Jonsson, Philip
Cheng, Michael L.
McBride, Sean
Kaeser, Christopher
Vargas, Herbert Alberto
Laudone, Vincent
Taylor, Barry S.
Kappagantula, Rajya
Baez, Priscilla http://orcid.org/0000-0001-7261-2872
Richards, Allison L.
Noronha, Anne Marie
Perera, Dilmi
Berger, Michael
Solit, David B. http://orcid.org/0000-0002-6614-802X
Iacobuzio-Donahue, Christine A.
Scher, Howard I.
Donoghue, Mark T. A.
Abida, Wassim
Schram, Alison M.
Article History
Received: 20 June 2022
Accepted: 30 January 2024
First Online: 14 February 2024
Competing interests
: The authors declare the following competing interests: AMS has received advisory board compensation from Relay Therapeutics and Mersana, and research funding paid to institution from AstraZeneca, ArQule, BeiGene, Black Diamond Therapeutics, Kura, Lilly, Merus, Northern Biologics, Pfizer, Relay, and Surface Oncology. Grant funding from ASCO Conquer Cancer Foundation CDA, NCI P30CA008748 CCITLA, Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748). MLC has received honoraria from The Lynx Group, WebMD, and Potomac Center for Medical Education, advisory board compensation from AstraZeneca, Inivata, Boehringer Ingelheim, and Mirati, research funding paid to institution from Palleon Pharmaceuticals, and travel, accommodations and expenses paid for by Daiichi Sankyo, AstraZeneca, and Genzyme. WA has received honoraria from Roche, Medscape, Aptitude Health, Clinical Education Alliance, OncLive/MJH Life Sciences, touchIME, Pfizer, and the MedNet. WA has also received advisory board compensation from Clovis Oncology, ORIC pharmaceuticals, Daiichi Sankyo, AstraZeneca/MedImmune, Pfizer and Laekna Therapeutics, and research funding from AstraZeneca, Zenith Epigenetics, Clovis Oncology, ORIC Pharmaceuticals, Epizyme, Nuvation Bio, Merus, and Transthera. The remaining authors declare no competing interests.